BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

Completed · Phase 3 · Has a placebo group

Conditions studied: Obesity

In brief

The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of treatment (Week 104)

Key facts

Study ID

NCT00395135

Run by

Eisai Inc.

People needed

3182

Starts

2006-11-01

Expected to finish

2009-02-01

Last updated by the study team

2019-10-02

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Obese adults with a BMI 30 to 45 kg/m2 or overweight adults with a BMI 27 to 29.9 kg/m2 and at least one obesity-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, glucose intolerance, sleep apnea)
• Ability to complete a 2 year study

You may not qualify if…

• Diabetes
• Pregnancy
• History of heart valve disease
• Serious or unstable current or past medical conditions

Where it is running

• Arena Pharmaceuticals, Inc. — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.